Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis

(2020) Chakradhar V Lagishetty et al.   CTS-Clinical and Translational Science

Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir

(2020) Yagai Bouba et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals

(2020) Luciana Lepore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

(2020) Michael Kozal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Choosing appropriate pharmacotherapy for drug-resistant HIV

(2019) Amedeo Capetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, HIV‐seronegative participants

(2019) Katy Moore et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients

(2019) Katy P Moore et al.   Open Forum Infectious Diseases

Fostemsavir

(2018) Pedro Cahn et al.   Current Opinion in HIV and AIDS

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment

(2017) Heather Sevinsky et al.   Open Forum Infectious Diseases

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial

(2016) Melanie Thompson et al.   ANTIVIRAL THERAPY

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

(2015) Jacob P Lalezari et al.   Lancet HIV

Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068

(2013) Neelanjana Ray et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068

(2013) N. Zhou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

(2012) Beata Nowicka-Sans et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

(2012) R. E. Nettles et al.   JOURNAL OF INFECTIOUS DISEASES